MX2023011240A - Composiciones farmaceuticas que comprenden zolmitriptan. - Google Patents
Composiciones farmaceuticas que comprenden zolmitriptan.Info
- Publication number
- MX2023011240A MX2023011240A MX2023011240A MX2023011240A MX2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A MX 2023011240 A MX2023011240 A MX 2023011240A
- Authority
- MX
- Mexico
- Prior art keywords
- zolmitriptan
- pharmaceutical compositions
- treatment
- aggression
- dementia
- Prior art date
Links
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title abstract 2
- 229960001360 zolmitriptan Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165938P | 2021-03-25 | 2021-03-25 | |
| US202263306377P | 2022-02-03 | 2022-02-03 | |
| PCT/US2022/021738 WO2022204399A1 (en) | 2021-03-25 | 2022-03-24 | Pharmaceutical compositions comprising zolmitriptan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011240A true MX2023011240A (es) | 2024-01-12 |
Family
ID=83397893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011240A MX2023011240A (es) | 2021-03-25 | 2022-03-24 | Composiciones farmaceuticas que comprenden zolmitriptan. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240189240A1 (https=) |
| EP (1) | EP4313037A4 (https=) |
| JP (1) | JP2024512069A (https=) |
| KR (1) | KR20240004330A (https=) |
| AU (1) | AU2022246101A1 (https=) |
| BR (1) | BR112023019407A2 (https=) |
| CA (1) | CA3213383A1 (https=) |
| IL (1) | IL307194A (https=) |
| MX (1) | MX2023011240A (https=) |
| WO (1) | WO2022204399A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117017983B (zh) * | 2023-10-09 | 2023-12-22 | 中山大学 | 曲普坦类药物在制备抗感染药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3090743A1 (en) * | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| US20100179202A1 (en) * | 2009-01-14 | 2010-07-15 | Ajanta Pharma Limited. | Orally disintegrating composition of zolmitriptan |
| CN104411301B (zh) * | 2012-04-18 | 2018-02-06 | 康特拉医药公司 | 适于改善运动障碍治疗的口服药物配方 |
| KR20160117596A (ko) * | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| HUE059559T2 (hu) * | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| ES3056138T3 (en) * | 2019-10-23 | 2026-02-18 | Maplight Therapeutics Inc | Methods of treating the symptoms of autism spectrum disorder |
-
2022
- 2022-03-24 US US18/552,420 patent/US20240189240A1/en active Pending
- 2022-03-24 EP EP22776651.6A patent/EP4313037A4/en active Pending
- 2022-03-24 CA CA3213383A patent/CA3213383A1/en active Pending
- 2022-03-24 IL IL307194A patent/IL307194A/en unknown
- 2022-03-24 BR BR112023019407A patent/BR112023019407A2/pt unknown
- 2022-03-24 WO PCT/US2022/021738 patent/WO2022204399A1/en not_active Ceased
- 2022-03-24 JP JP2023558740A patent/JP2024512069A/ja active Pending
- 2022-03-24 AU AU2022246101A patent/AU2022246101A1/en active Pending
- 2022-03-24 KR KR1020237036000A patent/KR20240004330A/ko active Pending
- 2022-03-24 MX MX2023011240A patent/MX2023011240A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023019407A2 (pt) | 2023-11-28 |
| AU2022246101A1 (en) | 2023-10-12 |
| KR20240004330A (ko) | 2024-01-11 |
| JP2024512069A (ja) | 2024-03-18 |
| WO2022204399A1 (en) | 2022-09-29 |
| EP4313037A4 (en) | 2025-02-26 |
| CA3213383A1 (en) | 2022-09-29 |
| US20240189240A1 (en) | 2024-06-13 |
| IL307194A (en) | 2023-11-01 |
| EP4313037A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| NZ784224A (en) | Parp1 inhibitors | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| SG10201407403UA (en) | Treatments For Gastrointestinal Disorders | |
| ATE551063T1 (de) | Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| CR20240144A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| ZA202110111B (en) | Methods and compositions for treating liver disorders | |
| MX2012014521A (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| PH12022552447A1 (en) | Nlrp3 modulators | |
| MX2022010868A (es) | Cepas bacterianas, las composiciones de las mismas y uso de las mismas en un procedimiento para el tratamiento de la deficiencia de vitamina d, y trastornos asociados a la misma. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| MX2023011240A (es) | Composiciones farmaceuticas que comprenden zolmitriptan. | |
| MX2023003089A (es) | Formas farmaceuticas solidas de bacterias. | |
| MX2021003651A (es) | Formulacion que comprende aceite ozonizado en el tratamiento de un tumor. | |
| WO2021004958A3 (en) | Compositions comprising bacterial strains | |
| WO2020023094A3 (en) | Treatment of lysosomal storage disorders | |
| MY203365A (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| MX2023008840A (es) | Formulaciones de oxitocina que contienen magnesio y metodos de uso. | |
| RU2008129232A (ru) | Способ лечения туберкулеза легких у больных вич-инфекцией |